文献速递前列腺癌

转移性激素敏感性前列腺癌联合治疗疗效的间接比较:系统综述与网络荟萃分析

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Eur Urol · 2019-11-01

该研究通过系统综述与网络荟萃分析,纳入7项随机试验,比较多西他赛、阿比特龙、恩扎卢胺或阿帕他胺联合ADT与ADT单药在mHSPC中的疗效。所有联合治疗均优于ADT单药,恩扎卢胺+ADT的OS风险比最低(HR 0.53,95%CI 0.37-0.75),成为延长OS首选治疗的概率估计为76.9%。不同联合治疗之间OS无显著差异。

要点

  • 所有联合治疗(多西他赛、阿比特龙、恩扎卢胺或阿帕他胺+ADT)均显著优于ADT单药。
  • 恩扎卢胺+ADT的OS风险比最低(HR 0.53,95%CI 0.37-0.75)。
  • 不同联合治疗之间OS无显著差异,选择需个体化。

核心结论

  • 多西他赛、阿比特龙、恩扎卢胺或阿帕他胺联合ADT均较ADT单药显著改善OS。
  • 不同联合治疗之间OS无显著差异,临床选择具有灵活性。

研究设计与样本

  • 系统综述与网络荟萃分析,检索多个数据库及主要会议摘要至2019年6月。
  • 纳入7项随机试验,入组接受一线治疗的转移性患者,比较ADT联合一种(或多种)紫杉类化疗或雄激素受体靶向治疗。

主要发现

  • 所有联合ADT的药物均优于ADT单药。
  • 恩扎卢胺+ADT对比ADT单药的绝对风险比最低(HR 0.53,95%CI 0.37-0.75)。
  • 恩扎卢胺+ADT成为延长OS首选治疗的概率估计为76.9%。
  • 低瘤负荷患者中恩扎卢胺的OS似优于多西他赛,但其他比较无差异。

关键数值与推荐

  • 主要终点为总生存(OS),次要终点为无进展生存。
  • 基于疾病体积进行亚组分析。

临床怎么用

  • 转移性激素敏感性前列腺癌患者应考虑 upfront 联合治疗而非ADT单药。
  • 临床决策需综合考虑多种因素,实施个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There have been substantial changes in the management of men with metastatic hormone-sensitive prostate cancer (mHSPC) over the past 5 yr, with upfront combination therapies replacing androgen-deprivation therapy (ADT) alone. A range of therapies have entered the space with no clear answer regarding their comparative efficacy. OBJECTIVE: To perform a systematic review and network meta-analysis to characterise the comparative efficacy of combination approaches in men with mHSPC. EVIDENCE ACQUISITION: We searched multiple databases and abstracts of major meetings up to June 2019 for randomised trials of patients receiving first-line therapy for metastatic disease, a combination of ADT and one (or more) of taxane-based chemotherapy, and androgen receptor-targeted therapies. The primary endpoint was overall survival (OS) and we evaluated progression-free survival as a secondary outcome. We performed subgroup analysis based on the volume of disease. EVIDENCE SYNTHESIS: We found seven trials that met our eligibility criteria using either docetaxel, abiraterone acetate, enzalutamide, or apalutamide in combination with ADT. All agents in combination with ADT were shown to be superior to ADT alone; enzalutamide + ADT had the lowest absolute hazard ratio compared with ADT only (hazards ratio 0.53, 95% confidence interval 0.37-0.75), and an estimated 76.9% probability that it is the preferred treatment to prolong OS compared with other combination treatments, or with ADT alone. Enzalutamide appeared to have better OS compared with docetaxel in men with low-volume disease, but there was no difference in other comparisons. CONCLUSIONS: Combination therapy with any of docetaxel, abiraterone acetate, enzalutamide, or apalutamide provides a significant OS benefit when compared with ADT alone. We did not identify significant differences in OS between different combination therapies. Subtle differences between these options provide clinicians considerable flexibility when selecting options for individual patients. PATIENT SUMMARY: Many men with metastatic, hormone-sensitive prostate cancer should be managed with upfront combination therapy instead of androgen-deprivation therapy alone. Clinicians may consider many factors during the decision-making process, and thus management should be tailored for patients individually.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2019. PMID: 31679970. doi:10.1016/j.eururo.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。